Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 21, 2019

SELL
$5.24 - $15.89 $3.77 Million - $11.4 Million
-720,000 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$5.1 - $11.89 $2.18 Million - $5.07 Million
-426,580 Reduced 37.2%
720,000 $8.56 Million
Q4 2018

Feb 14, 2019

BUY
$2.87 - $5.92 $3.29 Million - $6.79 Million
1,146,580 New
1,146,580 $3.61 Million

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $629M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Eventide Asset Management, LLC Portfolio

Follow Eventide Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.